Results 31 to 40 of about 8,546 (246)

Bumetanide for Core Symptoms of Autism Spectrum Disorder (BAMBI): A Single Center, Double-Blinded, Participant-Randomized, Placebo-Controlled, Phase Two, Superiority Trial.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020
OBJECTIVE Recent trials have indicated positive effects of bumetanide in autism spectrum disorder (ASD). We tested efficacy of bumetanide on core symptom domains using a mono-center, parallel-group, participant-randomized, double-blind, placebo ...
J. Sprengers, Dorinde M. van Andel, N. Zuithoff, M. Keijzer-Veen, Annelien J. A. Schulp, Floortje E. Scheepers, M. Lilien, B. Oranje, H. Bruining   +8 more
semanticscholar   +1 more source

Prediction of behavioral improvement through resting-state EEG and clinical severity in a randomized controlled trial testing bumetanide in autism spectrum disorder.

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021
BACKGROUND Mechanism-based treatments such as bumetanide are being repurposed for autism spectrum disorder (ASD). We recently reported beneficial effects on repetitive behavioral symptoms that might be related to regulating excitation-inhibition (E/I ...
E. Juarez-Martinez, J. Sprengers, G. Cristian, B. Oranje, Dorinde M. van Andel, Arthur-Ervin Avramiea, Sonja Simpraga, Simon J. Houtman, R. Hardstone, Cathalijn Gerver, Gert Jan van der Wilt, H. Mansvelder, M. Eijkemans, K. Linkenkaer-Hansen, H. Bruining   +14 more
semanticscholar   +1 more source

Improved symptoms following bumetanide treatment in children aged 3-6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial.

Science Bulletin, 2021
With the current limited drug therapy for the core symptoms of autism spectrum disorder (ASD), we herein report a randomized, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in ...
Yuan Dai, Lingli Zhang, Juehua Yu, Xin Zhou, Hua He, Yiting Ji, Kai Wang, Xiujuan Du, Xin Liu, Yun Tang, Shining Deng, Christelle Langley, Wei-Guang Li, Jun Zhang, Jianfeng Feng, B. Sahakian, Q. Luo, Fei Li   +17 more
semanticscholar   +1 more source

Application of a physiologically-based pharmacokinetic model for the prediction of bumetanide plasma and brain concentrations in the neonate [PDF]

, 2020
Bumetanide is a loop diuretic that is proposed to possess a beneficial effect on disorders of the central nervous system, including neonatal seizures.
Donovan, Maria D., Abduljalil, Khaled, Griffin, Brendan T., Boylan, Geraldine B., Cryan, John F.   +4 more
core   +1 more source

Reply to the commentary by Ben‐Ari and Delpire: Bumetanide and neonatal seizures: Fiction versus reality

Epilepsia, 2021
In this response to a commentary by Ben‐Ari and Delpire on our recent study on the pharmacology of neonatal seizures in a novel, physiologically validated rat model of birth asphyxia, we wish to rectify their inaccurate descriptions of our model and data.
W. Löscher, K. Kaila
semanticscholar   +1 more source

A Pilot Randomized, Controlled, Double-Blind Trial of Bumetanide to Treat Neonatal Seizures

Annals of Neurology, 2020
In the absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor drug efficacy. We tested bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standard‐therapy control group.
J. Soul, A. Bergin, C. Stopp, B. Hayes, Avantika Singh, Carmen Rosa Fortuno, Deirdre O’Reilly, K. Krishnamoorthy, Frances E Jensen, Valerie Rofeberg, M. Dong, A. Vinks, D. Wypij, K. Staley   +13 more
semanticscholar   +1 more source

Beta-Amyloid (Aβ_1-42) Increases the Expression of NKCC1 in the Mouse Hippocampus

Molecules, 2022
Alzheimer’s disease (AD) is a neurodegenerative disorder with an increasing need for developing disease-modifying treatments as current therapies only provide marginal symptomatic relief.
Patricia Lam, Chitra Vinnakota, Beatriz Calvo-Flores Guzmán, Julia Newland, Katie Peppercorn, Warren P. Tate, Henry J. Waldvogel, Richard L. M. Faull, Andrea Kwakowsky   +8 more
doaj   +1 more source

Effect of the combination of bumetanide plus chlorthalidone on hypertension and volume overload in patients with chronic kidney disease stage 4–5 KDIGO without renal replacement therapy: a double-blind randomized HEBE-CKD trial

BMC Nephrology, 2022
Background The co-administration of loop diuretics with thiazide diuretics is a therapeutic strategy in patients with hypertension and volume overload.
Fabio Solis-Jimenez, Lucia Monserrat Perez-Navarro, Ricardo Cabrera-Barron, Jesus Antonio Chida-Romero, Geovana Martin-Alemañy, Edgar Dehesa-López, Magdalena Madero, Rafael Valdez-Ortiz   +7 more
doaj   +1 more source

Inhibition of NKCC1 Modulates Alveolar Fluid Clearance and Inflammation in Ischemia-Reperfusion Lung Injury via TRAF6-Mediated Pathways

Frontiers in Immunology, 2018
Background: The expression of Na-K-2Cl cotransporter 1 (NKCC1) in the alveolar epithelium is responsible for fluid homeostasis in acute lung injury (ALI). Increasing evidence suggests that NKCC1 is associated with inflammation in ALI.
Chih-Hao Shen, Chih-Hao Shen, Chih-Hao Shen, Jr-Yu Lin, Yung-Lung Chang, Shu-Yu Wu, Chung-Kan Peng, Chin-Pyng Wu, Kun-Lun Huang, Kun-Lun Huang   +9 more
doaj   +1 more source

Loop Diuretics Inhibit Ischemia-Induced Intracellular Ca2+ Overload in Neurons via the Inhibition of Voltage-Gated Ca2+ and Na+ Channels

Frontiers in Pharmacology, 2021
One consequence of ischemic stroke is disruption of intracellular ionic homeostasis. Intracellular overload of both Na+ and Ca2+ has been linked to neuronal death in this pathophysiological state.
Christopher Katnik, Javier Cuevas
doaj   +1 more source